CTOs on the Move

Cardioxyl Pharmaceuticals

www.cardioxyl.com

 
Cardioxyl Pharmaceuticals is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.cardioxyl.com
  • 1450 Raleigh Rd Ste 212
    Chapel Hill, NC USA 27517
  • Phone: 919.869.8585

Executives

Name Title Contact Details

Similar Companies

Calliditas Therapeutics AB

Developing high-value, global products for patients with significant unmet medical needs in niche indications

Pharma-Logic Development

Pharma-Logic Development is a San Rafael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease.   Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.

HatchMed

HatchMed - Bringing user centric design into the medical equipment world https://t.co/7vuyMSBnct #hospital #nurseproof #Seattle

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).